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A Single Recurrent Mutation
in the 50-UTR of IFITM5
Causes Osteogenesis Imperfecta Type V
Tae-Joon Cho,1,10,* Kyung-Eun Lee,2,5,10 Sook-Kyung Lee,2,5,10 Su Jeong Song,2,5 Kyung Jin Kim,2,5
Daehyun Jeon,3,5 Gene Lee,3,5 Ha-Neui Kim,4,5 Hye Ran Lee,1 Hye-Hyun Eom,6 Zang Hee Lee,4,5
Ok-Hwa Kim,7 Woong-Yang Park,6 Sung Sup Park,8 Shiro Ikegawa,9 Won Joon Yoo,1 In Ho Choi,1
and Jung-Wook Kim2,3,5,*
Osteogenesis imperfecta (OI) is a heterogenous group of genetic disorders of bone fragility. OI type V is an autosomal-dominant disease
characterized by calcification of the forearm interosseousmembrane, radial head dislocation, a subphyseal metaphyseal radiodense line,
and hyperplastic callus formation; the causative mutation involved in this disease has not been discovered yet. Using linkage analysis in
a four-generation family and whole-exome sequencing, we identified a heterozygous mutation of c.14C>T in the 50-untranslated
region of a gene encoding interferon-induced transmembrane protein 5 (IFITM5). It completely cosegregated with the disease in three
families and occurred de novo in five simplex individuals. Transfection of wild-type and mutant IFITM5 constructs revealed that the
mutation added five amino acids (Met-Ala-Leu-Glu-Pro) to the N terminus of IFITM5. Given that IFITM5 expression and protein local-
ization is restricted to the skeletal tissue and IFITM5 involvement in bone formation, we conclude that this recurrent mutation would
have a specific effect on IFITM5 function and thus cause OI type V.Osteogenesis imperfecta (OI) is a heterogeneous group
of disorders characterized by intrinsic bone fragility, result-
ing in frequent fractures as well as in deformities of
the spine and limbs. The phenotypic severity of OI ranges
from perinatal lethal to subtle fracture susceptibility
or generalized osteopenia. The Sillence classification sys-
tem1 categorizes OI individuals into four types (type I
[MIM 166200], type II [MIM 166210], type III [MIM
259420], and type IV [MIM 166220]), and types V (MIM
610967), VI (MIM 613982), and VII (MIM 610682) have
subsequently been added on the basis of characteristic
phenotypes and laboratory findings.2 About 90% of OI
individuals fit into one of the types I through IV; their
conditions are caused by dominant mutations of either
COL1A1 (MIM 120150) or COL1A2 (MIM 120160). Muta-
tions in SERPINF1 (MIM 172860) and CRTAP (MIM
605497) were found responsible for OI types VI and
VII, respectively.3,4 Further mutations responsible for
autosomal-recessive OI were identified in LEPRE1 (MIM
610339),5 PPIB (MIM 123841),6 SERPINH1 (MIM
600943),7 and FKBP10 (MIM 607063),8 which lead to the
molecular-genetic division of OI into 11 types.9 However,
given the discovery of a large number of genes responsible
for recessive OI forms, the genotype-phenotype relation-
ships are difficult to explain. It has been suggested that
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OI type V is a specific disease entity with distinguishing
clinical and radiological features, and its causative muta-
tion has not been discovered yet. It is characterized by an
autosomal-dominant inheritance pattern, absence of blue
sclera, absence of dentinogenesis imperfecta, propensity
to hyperplastic callus formation, calcification of the fore-
arm interosseous membrane, radial-head dislocation, and
a subphyseal metaphyseal radiodense line (Figure 1).11,12
It is a dominantly inherited OI subtype not related to
COL1A1 and COL1A2 mutations.13
To identify the causative mutation for OI type V, we
recruited 19 Korean individuals with the disease: 13
affected individuals from three families and six simplex
individuals (Figure S1 in the Supplemental Data available
with this article online). This study was approved by the
institutional review boards of Seoul National University
Hospital and Seoul National University Dental Hospital.
Informed consent was obtained from all subjects. The clin-
ical and radiographic findings of 12 affected individuals
(11 familial and one simplex) were reported previously.14
An additional seven individuals (two familial and five
simplex) were included in this study. Their clinical and
radiographic features are summarized in Table 1. The
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Figure 1. Radiologic Findings for OI Type V
(A) The forearm of individual II:1 from family 9 at 15 years of age shows calcification of the interosseous membrane without radial-head
dislocation.
(B) The forearm of individual II:2 from family 3 at 27 years of age shows calcification of the interosseous membrane with radial-head
dislocation.
(C) The left femur i of individual II:1 from family 4 at 7 years of age. Note hyperplastic callus after open reduction of the femur shaft
fracture.
(D) Scoliosis and vertebral body collapse in individual IV:6 from family 1 at 11 years of age.(2 to þ2 SD), but seven individuals were markedly short
when their height was plotted against normal Korean
growth curves. Most individuals had less than ten frac-
tures; however, three individuals had 20–30 fractures.
Physical impairment ranged from an individual’s being
wheel-chair-bound to no physical impairment. All affected
individuals showed various degrees of calcification of the
forearm interosseous membrane, and radial-head disloca-
tion was observed in those individuals older than 20 years
of age, except that it was also observed in an 8-year-old boy
(family 5-II:1). Sanger sequencing and deletion/duplica-
tion analysis using MLPA for COL1A1 and COL1A2 failed
to show pathogenic mutations in the index individuals
of three familial cases or any other simplex individuals.
To identify the disease locus, we performed genome-
wide linkage analysis on a four-generation family (family
1 in Figure S1). Using 407 microsatellite markers with an
average interval of 10 cM, we genotyped 14 family
members (nine affected and five unaffected). A maximum
LOD score of 2.52 was obtained at D11S4046. Additional
markers defined the locus at the 11pter-11p15.4 re-
gion spanning 9.1 Mb from D11S4149 (Figure S1 and
Table S1). Sanger sequencing performed on the coding
region and exon-intron boundaries of the 171 genes in
this region failed to identify a causative mutation. Cytoge-
netic analysis revealed no significant structural change in
the chromosome, and aCGH showed no pathogenic
copy-number variation.
Then, we performed whole-exome sequencing in all four
members of family 4 (Figure S1) by using the Illumina344 The American Journal of Human Genetics 91, 343–348, August 1TruSeq DNA sample prep kit and 90 bp paired-end
sequencing on an Illumina HiSeq 2000. High-quality
sequencing data with an average of 95.1% coverage and
42.13 sequencing depth were obtained (Table S2). Align-
ment of the sequencing data to the NCBI human reference
genome (NCBI build 37.2, hg19) was performed, and the
sequence variations were annotated with dbSNP build 135.
Sequence variations (including those of the 50-untrans-
lated region [50-UTR], 30-UTR, and intron region) unique
to the proband were selected manually. Among the varia-
tions located in the linked region of family 1 (Table S3),
we focused on a heterozygous change in a gene encoding
interferon-induced transmembrane protein 5 (IFITM5);
this change was a transition from C to T in the 50-
UTR (c.–14C>T) (Figure 2) (RefSeq accession number
NM_001025295.1). Sanger sequencing confirmed that
this variation completely cosegregated with the disease
in family 1 (Table S4). The variation was found in all
affected individuals and not in unaffected family members
who participated. Furthermore, it was not found in 200
unrelated normal chromosomes from individuals with
the same ethnic background. Cosegregation in the other
two families (families 2 and 3, Figure S1) and de novo
occurrence in the five simplex individuals confirmed that
this variation is a disease-causing mutation of OI type V.
The mutation was predicted to generate an in-frame
translation start codon that would add five amino acids
(Met-Ala-Leu-Glu-Pro) to the N terminus of IFITM5.
Because we did not have any cultured IFITM5-expressing
cells from the affected individuals at hand, we transfected0, 2012
Table 1. Clinical and Radiological Data of the Individuals
Individual Age (yr) Sex
Height
(z Valuea) BMDb CFIM
Radial-Head
Dislocation
Number of
Fracturesc
Hyperplastic
Callus Scoliosis
Disability at Other than
Elbow or Forearm Physical Activity
Family 1-II:1 82 M 4.09a N.A. þ þ 1 N.A. þ - Appropriate for age
Family III:1 59 F 2.43a N.A. þ þ 4 N.A. þ - No limitation in daily life
Family III:3 46 F 0.9a N.A. þ þ 1 N.A. þ - No limitation in daily life
Family III:5 52 M 0.94a N.A. þ þ 4 N.A. þ - No limitation in daily life
Family IV:2 34 F 0.14a N.A. 5 þ 2 N.A. - - No limitation in daily life
Family IV:3 32 M 0.11a N.A. þ þ 10 N.A. þ - No limitation in daily life
Family IV:4 32 M 0.94a N.A. þ þ 5 N.A. N.A. - No limitation in daily life
Family IV:6 11 M 1.88 0.289/4.3/NA/0 þ - ~10 - þ - Unlimited ambulation,
cannot run
Family V:1 8 M 0.80 0.584/2.6/NA/13.5 þ - 5 - - - Can sprint
Family 2-II:2 49 M 3.21a N.A. þ þ 7~9 þ þ Bony ankylosis of both hips Independent ambulation
with a cane
Family III:1 20 F 2.43 0.681/10.5/1.27/0 þ þ 15 þ - - Can run slowly
Family 3-II:2 27 F 2.05 N.A. þ þ ~30 þ - - No limitation in daily life
Family III:1 6 F 0.02 0.64/4.8/NA/10.5 þ - ~20 þ - Ankylosis of elbow, left Independent but limited
ambulation
Family 4-II:1 7 M 2.52 0.339/5.2/-3.70/3.5 þ - ~5 þ - - Can run slowly
Family 5-II:1 8 F 1.96 0.264/0.8/NA/0 þ þ ~20 þ þ - Can sprint
Family 6-II:1 4 F 0.03 0.401/3.9/NA/0 þ - ~10 þ - - Can run slowly
Family 7-II:1 2 F 1.76 N.A. þ - 8 þ - - Starts independent
ambulation
Family 8-II:1 14 M 0.77 0.640/5.7/0.05/12 þ 5 ~10 - þ Migrating bone pain Wheelchair bound due to
painful LOM, both knees
and elbows
Family 9-II:1 16 M 3.84 0.504/7.9/1.87/0 þ - ~10 þ þ SNHL Can run slowly
Abbreviations are as follows: CFIM, calcification of the forearm interosseous membrane; N.A., information not available; LOM, limit of motion; and SNHL, sensorineural hearing loss.
aThe z value was calculated from 2007 data collected from normal children and young adults of the Korean population. Because people from the old Korean generation tend to be shorter, the z values of those over 30 years of
age should be underestimated.
bBone mineral density measured by dual-energy X-ray absorptiometry (DXA) is described as BMD at L2-4 (g/cm2)/age at measurement (year)/calculated z value/accumulated dose of pamidronate infused before the measure-
ment (mg/kg). z value could be calculated from 5 years of age.
cThe number of fractures was recorded according to the affected individual’s and/or parents’ memory.
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Figure 2. Mutation of IFITM5 in OI Type V
Schematic representation of IFITM5 is shown under the linked region (11pter-11p15.4). Dark green boxes indicate coding exons, and
bright green boxes indicate UTRs. The mutation (c.14C>T) is indicated by the red arrow, and the additional five amino acids generated
by this mutation are shown under the gene sequence. The sequencing chromatogram of an affected individual is shown below.wild-type and mutant IFITM5 constructs to investigate
their translation. The PCR product of IFITM5 that had
been amplified from cDNA from the DF/HCC DNA
Resource Core (Boston, MA) with primers introducing
HindIII and BamHI sequences (Table S4) was cloned. PCR
mutagenesis introduced the mutations c.14C>T and/or
c.2T>C (Table S4). The wild-type and three mutated
cDNAs (c.14C>T, c.2T>C, and both) were subcloned
into pEGFPN1 vector with HindIII and BamHI. HEK293
cells were transiently transfected with lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA). Immunoblot analysis
of the transfected cell lysates revealed that the translation
started at the start codon generated by the mutation, not
at the original start codon (Figure 3). It confirmed that the
mutation generates a mutated form of IFITM5 having five
additional amino acids at its N terminus.Figure 3. In Vitro Translation Assay
Total cell lysates of HEK293 cells transfected with three mutated
cDNAs (c.2T>C, c.14C>T, and both), wild-type, or wild-type
along with c.14C>T cDNA were immunoblotted with GFP anti-
body. When the original start codon was mutated (c.2T>C), no
translation was observed. Translation started at the start codon
generated by the mutation (c. 14C>T) regardless of the status
of the original start codon. Its translaton product was slightly
larger than that of the wild-type. Cotransfection with wild-type
and c.14C>T-mutated constructs produced double bands.
GAPDH was used as an internal control.
346 The American Journal of Human Genetics 91, 343–348, August 1We investigated postnatal spatial localization of IFITM5
by using polyclonal rabbit IFITM5 antibody (Abgent, San
Diego, CA) at a 1:50 dilution to conduct an immunohisto-
chemical study on the proximal tibia from a 3-week-old
female BALB/c mouse. IFITM5 immunoreactivity was
localized at the osteoblasts; periosteum; periphyseal fibro-
chondrosseous structure, including the groove of Ranvier
and the ring of LaCroix; and the superficial chondrocytes
of the articular cartilage; but not at the physeal chondro-
cytes (Figure S2). We also examined the mRNA expression
of IFITM5 in various human tissues, including bone, carti-
lage, hip joint capsule, circulating leukocytes, fascia lata,
ligamentum teres, muscle, and skin by RT-PCR with
gene-specific primers (Table S4). IFITM5 was expressed
exclusively in the bone and cartilage in humans, and
IFITM5 immnunoreactivity was localized at the osteo-
blasts, periosteum, perichondrium, and superficial layer
of articular cartilage (Figure S2).
IFITM5 is a member of the interferon-induced trans-
membrane gene family. It is located in chromosomal
region 11p15.5 and encodes a 132 amino acid protein,
which has two transmembrane domains, such that it has
extracellular N and C termini and an intracellular loop.15
Although IFITM5 was named because it is clustered close
to other IFITM family members and because it has an
IFITM-like gene structure, it does not have interferon
response elements and is not induced by interferons.15
Hence, another name, bone-restricted ifitm-like protein
(BRIL), was suggested.15 The N and C termini would be
the most likely domains to interact with other proteins
or cells.15 The function of IFITM5 has not been well eluci-
dated, but it was suggested to be involved in the process of
bone formation. Its mRNA expression and protein localiza-
tion are highly restricted to the skeletal tissue. In situ
hybridization and immunohistochemistry of mouse
embryos showed Ifitm5 expression and protein localiza-
tion at the osteoblasts of the long bones, vertebrae, facial0, 2012
bones, and the periosteum, but not at the proliferating and
resting zones of the growth plate or other soft-tissue
organs.15,16 Our data indicate similar spatial mRNA expres-
sion and protein localization patterns in postnatal mice
and humans.
Ifitm5 overexpression in UMR106 cells and primary
rat osteoblasts resulted in a dose-dependent increase in
mineralization, whereas knockdown of Ifitm5 by shRNA
in MC3T3 osteoblasts induced reduced mineralization.15
However, Ifitm5 knockout mice showed less critical change
than expected. Ifitm5/ mice had bent and smaller long
bones than Ifitm5þ/ mice, but there was no significant
difference in bone morphometric parameters between
Ifitm5/ and Ifitm5þ/ mice.16 Hence, simple loss-of-
function of IFITM5 cannot explain the complex pheno-
type of OI type V.
The mutation identified in this study is unique in that it
occurs in a UTR. We missed this mutation in the linkage
analysis and subsequent Sanger sequencing of candidate
genes because we paid attention only to the coding and
splicing regions. Additionally, it is unique in that all
affected individuals from nine unrelated families share
the same mutation in IFITM5. This suggests that the muta-
tionmight have a specific effect on the function of IFITM5.
Unlike individuals with type-I-collagen-related OI, individ-
uals with OI type V showed a relatively normal texture
of soft tissues, as detected during a surgical procedure
(unpublished data), absence of dentinogenesis imperfecta,
and involvement of non-calcified connective tissue such
as the forearm interosseous membrane. These findings
indicate that OI type V might be a disorder of skeletal
bone deposition rather than a generalized connective-
tissue disease.
In light of the contradictory components of the OI type
V phenotype, such as osteopenia versus ectopic calcifica-
tion or hyperplastic callus formation, the effect of the
c.14C>T mutation might depend on the tissues where
it is expressed and the events that the tissues undergo.
The mutant IFITM5 seems to interfere with normal bone
formation in the cortical and trabecular bone tissue, result-
ing in osteopenia and subsequent bone fragility. However,
it develops ectopic calcification consistently at the forearm
interosseous membrane and less consistently at the sub-
periosteal region of the long bones. Hyperplastic callus
formation is an exaggerated response of bone formation
during bone healing; it is possibly provoked by post-
traumatic inflammatory reaction. A subphyseal metaphy-
seal radiodense line also develops paradoxically in the
osteopenic long bones. Therefore, we postulate that the
mutant IFITM5 having five additional amino acids at its
N terminus dysregulates the process of bone formation—
usually by suppressing bone formation but sometimes by
leading to the development of ectopic calcification or exag-
gerated bone formation in a certain location or in a certain
situation.
Given the consistent presence of the c.14C>T muta-
tion in IFITM5 in all affected individuals, the restrictedThe Americspatial pattern of IFITM5 expression and protein localiza-
tion, and its involvement in bone formation, we conclude
that this specific mutation is responsible for OI type V. The
mechanism by which this mutation leads to the disease is
probably related to site-specific dysregulation of bone
formation. Further study with a specific mutation knockin
mouse would elucidate the pathogenic mechanism of this
mutation and help us to better understand the physiologic
function of IFITM5.
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